Literature DB >> 28322201

Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy.

Bruno Solano de Freitas Souza1, Daniela Nascimento Silva2, Rejane Hughes Carvalho2, Gabriela Louise de Almeida Sampaio2, Bruno Diaz Paredes2, Luciana Aragão França2, Carine Machado Azevedo1, Juliana Fraga Vasconcelos1, Cassio Santana Meira1, Paulo Chenaud Neto2, Simone Garcia Macambira3, Kátia Nunes da Silva2, Kyan James Allahdadi2, Fabio Tavora4, João David de Souza Neto4, Ricardo Ribeiro Dos Santos2, Milena Botelho Pereira Soares5.   

Abstract

Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cruzi infection, is a major cause of heart failure in Latin America. Galectin-3 (Gal-3) has been linked to cardiac remodeling and poor prognosis in heart failure of different etiologies. Herein, we investigated the involvement of Gal-3 in the disease pathogenesis and its role as a target for disease intervention. Gal-3 expression in mouse hearts was evaluated during T. cruzi infection by confocal microscopy and flow cytometry analysis, showing a high expression in macrophages, T cells, and fibroblasts. In vitro studies using Gal-3 knockdown in cardiac fibroblasts demonstrated that Gal-3 regulates cell survival, proliferation, and type I collagen synthesis. In vivo blockade of Gal-3 with N-acetyl-d-lactosamine in T. cruzi-infected mice led to a significant reduction of cardiac fibrosis and inflammation in the heart. Moreover, a modulation in the expression of proinflammatory genes in the heart was observed. Finally, histological analysis in human heart samples obtained from subjects with Chagas disease who underwent heart transplantation showed the expression of Gal-3 in areas of inflammation, similar to the mouse model. Our results indicate that Gal-3 plays a role in the pathogenesis of experimental chronic Chagas disease, favoring inflammation and fibrogenesis. Moreover, by demonstrating Gal-3 expression in human hearts, our finding reinforces that this protein could be a novel target for drug development for Chagas cardiomyopathy.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28322201     DOI: 10.1016/j.ajpath.2017.01.016

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  Cystatin C and galectin-3 as therapeutic targets in heart failure.

Authors:  Christos Zivlas; Filippos Triposkiadis; Stelios Psarras; Gregory Giamouzis; Ioannis Skoularigis; Stavros Chryssanthopoulos; Alkistis Kapelouzou; Steve Ramcharitar; Edward Barnes; Evangelos Papasteriadis; Dennis Cokkinos
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-31

Review 2.  Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis.

Authors:  Hongsen Chen; Chensong Chen; Junjie Fang; Ren Wang; Wanshui Nie
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

3.  Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model.

Authors:  Fani Vlachou; Aimilia Varela; Konstantina Stathopoulou; Konstantinos Ntatsoulis; Evgenia Synolaki; Harris Pratsinis; Dimitris Kletsas; Paschalis Sideras; Constantinos H Davos; Yassemi Capetanaki; Stelios Psarras
Journal:  Cell Mol Life Sci       Date:  2022-04-19       Impact factor: 9.261

4.  Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation.

Authors:  Shingo Takahara; Mourad Ferdaoussi; Nikola Srnic; Zaid H Maayah; Shubham Soni; Anna K Migglautsch; Rolf Breinbauer; Erin E Kershaw; Jason R B Dyck
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-13       Impact factor: 4.733

5.  Soluble ST2, Galectin-3 and clinical prognosis of patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy: a correlation analysis.

Authors:  Bangrong Song; Bo Yao; Haiming Dang; Ran Dong
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

6.  Anti-inflammatory Role of Galectin-8 During Trypanosoma cruzi Chronic Infection.

Authors:  Adriano Bertelli; Liliana M Sanmarco; Carla A Pascuale; Miriam Postan; Maria P Aoki; María S Leguizamón
Journal:  Front Cell Infect Microbiol       Date:  2020-07-02       Impact factor: 5.293

7.  Time-course analysis of cardiac and serum galectin-3 in viral myocarditis after an encephalomyocarditis virus inoculation.

Authors:  Kei Noguchi; Hiroyuki Tomita; Tomohiro Kanayama; Ayumi Niwa; Yuichiro Hatano; Masato Hoshi; Shigeyuki Sugie; Hideshi Okada; Masayuki Niwa; Akira Hara
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

8.  Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.

Authors:  Madhavi P Gavini; Abuzar Mahmood; Anthony M Belenchia; Paige Beauparlant; Senthil A Kumar; Sivakumar Ardhanari; Vincent G DeMarco; Lakshmi Pulakat
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

9.  Galectin-3 Knockdown Impairs Survival, Migration, and Immunomodulatory Actions of Mesenchymal Stromal Cells in a Mouse Model of Chagas Disease Cardiomyopathy.

Authors:  Bruno Solano de Freitas Souza; Kátia Nunes da Silva; Daniela Nascimento Silva; Vinícius Pinto Costa Rocha; Bruno Diaz Paredes; Carine Machado Azevedo; Carolina Kymie Nonaka; Gisele Batista Carvalho; Juliana Fraga Vasconcelos; Ricardo Ribeiro Dos Santos; Milena Botelho Pereira Soares
Journal:  Stem Cells Int       Date:  2017-07-10       Impact factor: 5.443

10.  Granulocyte-Colony Stimulating Factor-Overexpressing Mesenchymal Stem Cells Exhibit Enhanced Immunomodulatory Actions Through the Recruitment of Suppressor Cells in Experimental Chagas Disease Cardiomyopathy.

Authors:  Daniela N Silva; Bruno S F Souza; Juliana F Vasconcelos; Carine M Azevedo; Clarissa X R Valim; Bruno D Paredes; Vinicius P C Rocha; Gisele B Carvalho; Pamela S Daltro; Simone G Macambira; Carolina K V Nonaka; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.